Changes at Hoya

Article

Hans Werquin will become CEO of Hoya Vision Care Europe from the beginning of April 2010. He will report to Gerald Bottero, who has been leading the European branch for the past five years. Bottero remains CEO of Hoya Vision Care globally.

Hans Werquin will become CEO of Hoya Vision Care Europe from the beginning of April 2010. He will report to Gerald Bottero, who has been leading the European branch for the past five years. Bottero remains CEO of Hoya Vision Care globally.

Werquin has 20 years experience in the optical industry and is currently President of Hoya Lens Belgium and Hoya Lens France. Based in Paris, he will remain President of both companies, while Frank Van de Perck and Patrice Pineau will be appointed Vice President of respectively Hoya Lens Belgium and Hoya Lens France.

“I strongly believe in involving and mobilizing our customers and all Hoya teams in the unique innovative technologies of the HOYA Group, and I will devote my vision, passion and accountability to uplift these core strengths of the HOYA Group within Europe,” said Werquin.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.